MMMichael P. Marks

Michael P. Marks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael P. Marks has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Mlynash

    Department of Neurology, Stanford University Medical Center, Stanford, California, USA

    4 shared publications
  • Greg Zaharchuk

    From Stanford Stroke Center, Stanford University School of Medicine, Palo Alto, CA

    3 shared publications
  • Huy M. Do

    Department of Radiology, Stanford University Medical Center, Stanford, California, USA; Department of Neurosurgery, Stanford University Medical Center, Stanford, California, USA

    3 shared publications
  • Maarten G. Lansberg

    Department of Neurology, Stanford University, CA (M.G.L., G.W.A.).

    3 shared publications
  • Mahesh V. Jayaraman

    Warren Alpert School of Medical at Brown University, Providence, Rhode Island, USA

    3 shared publications
  • Mary L. Marcellus

    Department of Radiology, Stanford University Medical Center, Stanford, California, USA; Department of Neurosurgery, Stanford University Medical Center, Stanford, California, USA

    3 shared publications

Latest Publications

  • Embolization Followed by Radiosurgery for the Treatment of Brain Arteriovenous Malformations (AVMs)

    by Michael P. Marks, Mary L. Marcellus, Justin Santarelli, Robert L. Dodd, Huy M. Do, Steven D. Chang, John R. Adler, Michael Mlynash, Gary K. Steinberg


  • Effect of Collateral Blood Flow on Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke

    by Michael P. Marks, Maarten G. Lansberg, Michael Mlynash, Jean-Marc Olivot, Matus Straka, Stephanie Kemp, Ryan McTaggart, Manabu Inoue, Greg Zaharchuk, Roland Bammer, et al.

    Background and Purpose—: Our aim was to determine the relationships between angiographic collaterals and diffusion/perfusion findings, subsequent infarct growth, and clinical outcome in patients undergoing endovascular therapy for ischemic stroke. Methods—: Sixty patients with a thrombolysis in cerebral infarction (TICI) score of 0 or 1 and internal carotid artery/M1 occlusion at baseline were evaluated. A blinded reader assigned a collateral score using a previous 5-point scale, from 0 (no collateral flow) to 4 (complete/rapid collaterals to the entire ischemic territory). The analysis was dichotomized to poor flow (0–2) versus good flow (3–4). Collateral score was correlated with baseline National Institutes of Health Stroke Scale, diffusion-weighted imaging volume, perfusion-weighted imaging volume (Tmax ≥6 seconds), TICI reperfusion, infarct growth, and modified Rankin Scale score at day 90. Results—: Collateral score correlated with baseline National Institutes of Health Stroke Scale ( P =0.002) and median volume of tissue at Tmax ≥6 seconds ( P =0.009). Twenty-nine percent of patients with poor collateral flow had TICI 2B–3 reperfusion versus 65.5% with good flow ( P =0.009). Patients with poor collaterals who reperfused (TICI 2B–3) were more likely to have a good functional outcome (modified Rankin Scale score 0–2 at 90 days) compared with patients who did not reperfuse (odds ratio, 12; 95% confidence interval, 1.6–98). There was no difference in the rate of good functional outcome after reperfusion in patients with poor collaterals versus good collaterals ( P =1.0). Patients with poor reperfusion (TICI 0–2a) showed a trend toward greater infarct growth if they had poor collaterals versus good collaterals ( P =0.06). Conclusions—: Collaterals correlate with baseline National Institutes of Health Stroke Scale, perfusion-weighted imaging volume, and good reperfusion. However, target mismatch patients who reperfuse seem to have favorable outcomes at a similar rate, irrespective of the collateral score. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01349946.


  • Open Access

    Angiographic Outcome of Endovascular Stroke Therapy Correlated with MR Findings, Infarct Growth, and Clinical Outcome in the DEFUSE 2 Trial

    by Michael P. Marks, Maarten G. Lansberg, Michael Mlynash, Stephanie Kemp, Ryan A. McTaggart, Greg Zaharchuk, Roland Bammer, Gregory W. Albers, for the DEFUSE Investigators

    Background: DEFUSE 2 demonstrated that patients with magnetic resonance imaging mismatch had a favorable clinical response to tissue reperfusion assessed by magnetic resonance imaging. This study reports the endovascular results and correlates angiographic reperfusion with clinical and imaging outcomes. Methods: Prospectively enrolled ischemic stroke patients underwent baseline magnetic resonance imaging and started endovascular therapy within 12 h of onset. Patients were classified as either target mismatch or no target mismatch using magnetic resonance imaging. The pre- and postprocedure angiogram was evaluated to determine thrombolysis in cerebral infarction scores. Favorable clinical response was determined at day 30, and good functional outcome was defined as a modified Rankin Scale 0–2 at day 90. Results: One-hundred patients had attempted endovascular treatment. At procedure end, 23% were thrombolysis in cerebral infarction 0–1, 31% thrombolysis in cerebral infarction 2A, 28% thrombolysis in cerebral infarction 2B, and 18% thrombolysis in cerebral infarction 3. More favorable thrombolysis in cerebral infarction-reperfusion scores were associated with greater magnetic resonance imaging reperfusion ( P < 0·001). thrombolysis in cerebral infarction scores correlated with 30-day favorable clinical response ( P = 0·041) and 90-day modified Rankin Scale 0–2 ( P = 0·008). These correlations were significant for target mismatch patients at 30 days ( P = 0·034) and 90 days ( P = 0·003). Infarct growth was strongly associated with poorer thrombolysis in cerebral infarction scores in target mismatch patients ( P < 0·001). Patients with thrombolysis in cerebral infarctionnfarction 2A reperfusion had less magnetic resonance imaging reperfusion ( P = 0·004) and poorer clinical outcome at 90 days ( P = 0·01) compared with thrombolysis in cerebral infarction 2B-3 patients. Conclusion: Thrombolysis in cerebral infarction reperfusion following endovascular therapy for ischemic stroke is highly correlated with magnetic resonance imaging reperfusion, infarct growth, and clinical outcome.


  • Correlation of AOL recanalization, TIMI reperfusion and TICI reperfusion with infarct growth and clinical outcome

    by Michael P Marks, Maarten G Lansberg, Michael Mlynash, Stephanie Kemp, Ryan McTaggart, Greg Zaharchuk, Roland Bammer, Gregory W Albers

    Objective To understand how three commonly used measures of endovascular therapy correlate with clinical outcome and infarct growth. Methods Prospectively enrolled patients underwent baseline MRI and started endovascular therapy within 12 h of stroke onset. The final angiogram was given a primary arterial occlusive lesion (AOL) recanalization score (0–3), a Thrombolysis in Myocardial Infarction (TIMI) score (0–3) and a Thrombolysis in Cerebral Infarction (TICI) score (0–3). The scores were dichotomized into poor revascularization (AOL 0–2, TIMI 0–1 and TICI 0–2a) versus good revascularization (AOL 3, TIMI 2–3, TICI 2b–3). Patients were classified according to whether or not they had target mismatch (TMM). Good outcome was defined as a 90-day modified Rankin Scale score of 0–2. Results Endovascular treatment was attempted in 100. A good outcome was achieved in 57% of patients with a TICI score of 2b–3 and in 24% of patients with a TICI score of 0–2a (p=0.001). Patients with TIMI scores of 2–3 and an AOL score of 3 had lower rates of good outcome (44% and 47%, respectively), which were not significantly better than those with TIMI scores of 0–1 or AOL scores of 0–2. In patients with TMM, these rates of good outcome improved with all the scoring systems and were significantly better for TIMI and TICI scores. Patients with a TICI score of 2a had rates of good functional outcome and lesion growth which were not different from those with TICI scores of 0–1 but were significantly worse than those with TICI scores of 2b–3. Conclusions TIMI 2–3 and TICI 2b–3 reperfusion scores demonstrated improved outcome in patients with tissue mismatch with a small infarct core and a larger hypoperfused region but AOL scores did not. Patients with a TICI score of 2a had a poorer outcome and more lesion growth than those with TICI scores of 2b–3.


  • Open Access

    Experimental Study of Intracranial Hematoma Detection with Flat Panel Detector C-Arm CT

    by H. Arakawa, M.P. Marks, H.M. Do, D.M. Bouley, N. Strobel, T. Moore, R. Fahrig

    BACKGROUND AND PURPOSE: Intracranial hemorrhage is a commonly acknowledged complication of interventional neuroradiology procedures, and the ability to image hemorrhage at the time of the procedure would be very beneficial. A new C-arm system with 3D functionality extends the capability of C-arm imaging to include soft-tissue applications by facilitating the detection of low-contrast objects. We evaluated its ability to detect small intracranial hematomas in a swine model. MATERIALS AND METHODS: Intracranial hematomas were created in 7 swine by autologous blood injection of various hematocrits (19%–37%) and volumes (1.5–5 mL). Four animals received intravascular contrast before obtaining autologous blood (group 1), and 3 did not (group 2). We scanned each animal by using the C-arm CT system, acquiring more than 500 images during a 20-second rotation through more than 200°. Multiplanar reformatted images with isotropic resolution were reconstructed on the workstation by using product truncation, scatter, beam-hardening, and ring-artifact correction algorithms. The brains were harvested and sliced for hematoma measurement and compared with imaging findings. RESULTS: Five intracranial hematomas were created in group 1 animals, and all were visualized. Six were created in group 2, and 3 were visualized. One nonvisualized hematoma was not confirmed at necropsy. All the others in both groups were confirmed. In group 1 (with contrast), small hematomas were detectable even when the hematocrit was 19%–20%. In group 2 (without contrast) C-arm CT was able to detect small hematomas (2) created with hematocrits of 29%–37%. The area of hematoma measured from the C-arm CT data was, on average, within 15% of the area measured from harvested brain. CONCLUSIONS: The image quality obtained with this implementation of C-arm CT was sufficient to detect experimentally created small intracranial hematomas. This capability should provide earlier detection of hemorrhagic complications that may occur during neurointerventional procedures.


    • 1 February 2007
      • Vol. 28  (2) , 352-354

    Treatment of Traumatic Cervical Arteriovenous Fistulas with N-Butyl-2-Cyanoacrylate

    by M.V. Jayaraman, H.M. Do, M.P. Marks

    SUMMARY: We report 2 cases of traumatic arteriovenous fistulas in the neck treated with transarterial embolization with n-butyl-2-cyanoacrylate (n-BCA). In both cases, covered stent placement across the fistula to preserve the artery was not possible. Detachable coil placement was attempted in one case but was not successful. Both fistulas were successfully treated with n-BCA embolization. To our knowledge, these are the first 2 such cases reported of high-flow cervical arteriovenous fistulas treated with n-BCA embolization.


  • Hemorrhage Rate in Patients With Spetzler-Martin Grades IV and V Arteriovenous Malformations

    by Mahesh V. Jayaraman, Mary L. Marcellus, Huy M. Do, Steven D. Chang, Jarrett K. Rosenberg, Gary K. Steinberg, Michael P. Marks

    Background and Purpose— We sought to examine the prospective annual risk of hemorrhage in patients harboring Spetzler-Martin grades IV and V arteriovenous malformations (AVMs) before and after initiation of treatment. Methods— Medical records of 61 consecutive patients presenting with Spetzler-Martin grades IV and V AVMs were retrospectively reviewed for demographics, angiographic features, presenting symptom(s), and time of all hemorrhage events, before or after treatment initiation. Pretreatment hemorrhage rates (excluding hemorrhages at presentation) and posttreatment rates were subsequently calculated. Modified Rankin Scale (mRS) scores before and after treatment were recorded. Results— The annual pretreatment hemorrhage rate for all patients was 10.4% per year (95% CI, 2.2 to 15.4%), 13.9% (95% CI, 3.5 to 22.1%) in patients with hemorrhagic presentation and 7.3% (2.6 to 14.3%) in patients with nonhemorrhagic presentation. Posttreatment hemorrhage rates were 6.1% per year (95% CI, 2.5 to 13.2%) for all patients, 5.6% (95% CI, 2.1 to 11.8%) for patients presenting with hemorrhage and 6.4% (95% CI, 1.6 to 10.1%) in patients with nonhemorrhagic presentation. A noninferiority test showed that the posttreatment hemorrhage rate was less than or equal to the pretreatment hemorrhage rate ( P Conclusions— The annual rate of hemorrhage in grades IV and V AVMs is higher in this series than reported for all AVMs, which may reflect some referral bias in this single-center study. Nevertheless, initiation of treatment does not appear to increase the rate of subsequent hemorrhage. Treatment for these lesions may be warranted, given their poor natural history.


  • Angioplasty for Symptomatic Intracranial Stenosis

    by Michael P. Marks, Joan C. Wojak, Firas Al-Ali, Mahesh Jayaraman, Mary L. Marcellus, John J. Connors, Huy M. Do

    Background and Purpose— Medical treatment of symptomatic intracranial stenosis carries a high risk of stroke. This study was done to evaluate the clinical and angiographic outcomes after intracranial angioplasty for this disease. Methods— A total of 120 patients with 124 intracranial stenoses were treated by primary angioplasty. All patients had neurologic symptoms (stroke or transient ischemic attack) attributable to intracranial stenoses ≥50%. Angiograms were evaluated before and after angioplasty for the degree of stenosis. Results— Pretreatment stenoses varied from 50% to 95% (mean 82.2±10.2). Post-treatment stenoses varied from 0% to 90% (mean 36.0±20.1). There were 3 strokes and 4 deaths (all neurological) within 30 days of the procedure, giving a combined periprocedural stroke and death rate of 5.8%. A total of 116 patients (96.7%) were available for a mean follow-up time of 42.3 months. There were 6 patients who had a stroke in the territory of treatment and 5 additional patients with stroke in other territories. Ten deaths occurred during the follow-up period, none of which were neurological. Including the periprocedural stroke and deaths, this yielded an annual stroke rate of 3.2% in the territory of treatment and a 4.4% annual rate for all strokes. Conclusion— Intracranial angioplasty can be performed with a high degree of technical success and a low risk of complications. Long-term clinical follow-up of intracranial angioplasty patients demonstrates a risk of future strokes that compares favorably to patients receiving medical therapy.